In short. Sun protection first and by a distance, then not smoking and topical retinoids. The rest of the category is thin, and the thinnest part is the largest.
Key points
- The interventions with support are cheap, unglamorous and not sold as longevity.
- The part of the category sold as longevity is large, pleasant to use and largely untested on the timescale it claims.
- That inversion is the most useful single observation about this subject.
The evidence in this subject is unevenly distributed, and the unevenness is extreme enough that the shape of it is worth learning. Support is strongest for the interventions that are least marketed, and thinnest for the part of the category that is largest.
Sun protection, first and by a distance
The strongest evidence in the whole field belongs to sun protection, and it is strong for two reasons. The studies behind it are long-running and population-based rather than short and small, which means the finding has survived the test that most of this category has never faced. And the mechanism is direct: reducing ultraviolet exposure reduces the accumulation of photodamage, which is the larger part of what ageing looks like. Its weakness is not scientific, it is behavioural, because the benefit depends on daily use and most people use less than they think.
Not smoking and topical retinoids
The second and third places are also established and also unglamorous. Smoking is associated with earlier and more pronounced facial ageing across studies and populations. Topical retinoids improve fine lines and surface texture over months, and their evidence is longer-running than that of any device in the category. Both come with limits: retinoids irritate, particularly at the start, and require continued use for the effect to persist.
Where the evidence is, and where the market is
The interventions with support are cheap, unglamorous and not sold as longevity. The part of the category sold as longevity is large, pleasant to use and largely untested on the timescale it claims. That inversion is the most useful single observation about this subject.
Devices, in their own place
Devices treat findings that are present rather than a rate of ageing, and they are approved for endpoints such as pigment, texture and wrinkles. That is a real capability and a limited one, and it is graded that way here. Where a device is presented as a longevity intervention, the presentation has usually borrowed the category word and left the endpoint behind.
The thin part
Supplements, drinks and programmes make up most of the category by volume and have the least behind them. Antioxidants have a mechanism and no demonstrated effect on how skin ages in people. Ingested collagen is digested into its constituent amino acids and is not routed to the skin. A laboratory result is a reason to study something and not a result, and the gap between the two is where the longevity market lives.
The evidence, in order
- Sun protection: long-running population studies, the strongest evidence in the field.
- Not smoking, and topical retinoids for fine lines over months.
- Devices: real for findings that are present, not for the rate of ageing.
Everything else in the category sits below those three lines, and most of it sits well below.
Frequently asked questions
Which intervention has the strongest evidence?
Sun protection, by a wide margin. It is supported by long-running studies in whole populations rather than by short trials in small groups, it applies to everyone rather than to a subgroup, and the mechanism is direct. Its weakness is not the evidence but the consistency of use, because the benefit depends on daily protection rather than occasional.
Where do topical retinoids sit?
Established for fine lines and surface texture over months, and among the better-studied topical treatments in the field. They require continued use for the effect to persist and cause irritation in a proportion of people, particularly at the start. What is established is a change in specific findings rather than a change in the rate of ageing.
What about the rest of the category?
Thin. Antioxidant supplements have a mechanism and no demonstrated effect on how skin ages in people. Collagen taken by mouth is digested into its constituent amino acids rather than routed to the skin. Programmes and devices treat findings that are present. The largest part of the category by marketing volume has the least evidence behind it.
Risks & Limitations
- Sun protection has the strongest evidence in the field and almost no downside; almost nothing else in the category does.
- Nothing is approved as a treatment for skin ageing itself, and approvals belong to products and defined endpoints.
- Topical retinoids irritate and require continued use; devices carry burn, pigment change and scarring.
- Supplements, drinks and programmes sold as longevity have no demonstrated effect on how skin ages in people.
- A mechanism is a reason to study something rather than a result, and a treated finding can recur.
When to Seek Care
- A mole or patch that is changing in size, shape or colour — have it assessed by a clinician.
- A lesion that bleeds, itches or will not heal — have it assessed by a clinician.
- Blistering, crusting or pigment change that follows a device treatment — have it assessed by a clinician.
- A rash, or irritation from a topical that does not settle when use is paused, is assessed by a clinician rather than managed indefinitely.
References & Further Reading
- World Health Organization (WHO) — ultraviolet radiation and skin cancer prevention guidance
- U.S. Food and Drug Administration (FDA) — sunscreen and topical product labelling and indications
- National Medical Products Administration (NMPA, China) — approved products and their indications
- Cochrane Library — systematic reviews of topical treatments and photoprotection
- Chinese Medical Association Dermatology Branch — clinical guidance
This page is a review of published evidence and regulation, not medical advice, and it does not cite individual studies. It is not a booking page and it does not recommend a product or treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.